Data Favor Max Resection for All Glioblastomas Bookmark

Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

A large, retrospective study demonstrates that surgical removal of as much tumor tissue as possible results in the best outcomes for patients—seems pretty logical, and is true.

Go to full article published by MedPage Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

The Evolutionary History of 2,658 Cancers Bookmark

Research paper from Nature curated by Editor in Chief George Lundberg, MD, who notes: 

A massive study of thousands of cancers that explores the genomic basis for cancer is being reported simultaneously in dozens of journals. Nature has published this summary article.

Go to full paper published in Nature.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline Bookmark

Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

There has been confusion about how to conduct follow-up for a patient with lung cancer who has received therapy intended to cure. This new guideline intends to clarify best practice.

Go to full paper published in the Journal of Clinical Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Carcinoma of Unknown Primary Case Reviewed in Tumor Board Session Bookmark

Article from CAP Today curated by Editor in Chief George Lundberg, MD, who notes: 

Tumor boards are an established method of dealing with problem cancer cases. In precision oncology, they may, even must, be molecular. This is a great example of how a molecular tumor board can provide actionable insights for patients.

Go to full article published by CAP Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Estimating the Magnitude of Cancer Overdiagnosis in Australia Bookmark

Research paper from the Medical Journal of Australia curated by Editor in Chief George Lundberg, MD, who notes: 

For five types of cancer, the rate of overdiagnosis in Australia is roughly one in five. Many of these diagnoses are “indolentomas” or “incidentalomas.”

Go to full paper published in the Medical Journal of Australia.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

‘Impressed With Impact’ of Ketamine in Cancer Palliative Care Bookmark

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Blood-Based Screening Test May Aid in Detecting GI Cancers Bookmark

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

Early diagnosis remains a key for therapeutic success in gastrointestinal (GI) cancers. The sensitivity and specificity of these blood tests are encouraging.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Grants Priority Review to Olaparib, Bevacizumab Combination for Ovarian Cancer Bookmark

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

In precision oncology, drugs combinations may provide new effective treatment.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Approves Lynparza as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer Bookmark

Article from The Cancer Letter curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza) for marketing and sales for a narrow group of metastatic pancreatic cancer patients, based on rates of progression-free survival in a clinical trial published in The New England Journal of Medicine.

Go to full article published by The Cancer Letter.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Cancer Data Provide Insights into Occurrence, Overdiagnosis, and Treatment Advances Bookmark

Article from ScienceDaily curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by ScienceDaily.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.